Clasp Therapeutics took off with $150 million in Series A financing to develop a portfolio of next-generation immunotherapies that are both personalized and off-the-shelf to target hard-to-treat tumors. Based in Cambridge, Massachusetts and Rockville, Maryland, the startup garnered attention from…